Search Results - "Evans, Kurt W."

Core epithelial-to-mesenchymal transition interactome gene-expression signature is associated with claudin-low and metaplastic breast cancer subtypes by Taube, Joseph H., Herschkowitz, Jason I., Komurov, Kakajan, Zhou, Alicia Y., Gupta, Supriya, Yang, Jing, Hartwell, Kimberly, Onder, Tamer T., Gupta, Piyush B., Evans, Kurt W., Hollier, Brett G., Ram, Prahlad T., Lander, Eric S., Rosen, Jeffrey M., Weinberg, Robert A., Mani, Sendurai A.

“…The epithelial-to-mesenchymal transition (EMT) produces cancer cells that are invasive, migratory, and exhibit stem cell characteristics, hallmarks of cells…”
Get full text

Epithelial-mesenchymal transition and cancer stem cells: a dangerously dynamic duo in breast cancer progression by May, Caitlin D, Sphyris, Nathalie, Evans, Kurt W, Werden, Steven J, Guo, Wenjun, Mani, Sendurai A

“…Aberrant activation of a latent embryonic program - known as the epithelial-mesenchymal transition (EMT) - can endow cancer cells with the migratory and…”
Get full text

Cyclin E Overexpression Sensitizes Triple-Negative Breast Cancer to Wee1 Kinase Inhibition by Chen, Xian, Low, Kwang-Huei, Alexander, Angela, Jiang, Yufeng, Karakas, Cansu, Hess, Kenneth R, Carey, Jason P W, Bui, Tuyen N, Vijayaraghavan, Smruthi, Evans, Kurt W, Yi, Min, Ellis, D Christian, Cheung, Kwok-Leung, Ellis, Ian O, Fu, Siqing, Meric-Bernstam, Funda, Hunt, Kelly K, Keyomarsi, Khandan

“…Poor prognosis in triple-negative breast cancer (TNBC) is due to an aggressive phenotype and lack of biomarker-driven targeted therapies. Overexpression of…”
Get full text

FOXC2 Expression Links Epithelial―Mesenchymal Transition and Stem Cell Properties in Breast Cancer by HOLLIER, Brett G, TINNIRELLO, Agata A, HERSCHKOWITZ, Jason I, GUERRA, Rudy, CHANG, Jeffrey T, MIURA, Naoyuki, ROSEN, Jeffrey M, MANI, Sendurai A, WERDEN, Steven J, EVANS, Kurt W, TAUBE, Joseph H, SARKAR, Tapasree Roy, SPHYRIS, Nathalie, SHARIATI, Maryam, KUMAR, Sreedevi V, BATTULA, Venkata L

“…Resistance to chemotherapy and metastases are the major causes of breast cancer-related mortality. Moreover, cancer stem cells (CSC) play critical roles in…”
Get full text

Selinexor (KPT-330) demonstrates anti-tumor efficacy in preclinical models of triple-negative breast cancer by Arango, Natalia Paez, Yuca, Erkan, Zhao, Ming, Evans, Kurt W, Scott, Stephen, Kim, Charissa, Gonzalez-Angulo, Ana Maria, Janku, Filip, Ueno, Naoto T, Tripathy, Debu, Akcakanat, Argun, Naing, Aung, Meric-Bernstam, Funda

“…Selinexor (KPT-330) is an oral agent that has been shown to inhibit the nuclear exporter XPO1. Given the pressing need for novel therapies for triple-negative…”
Get full text

A Population of Heterogeneous Breast Cancer Patient-Derived Xenografts Demonstrate Broad Activity of PARP Inhibitor in BRCA1/2 Wild-Type Tumors by Evans, Kurt W, Yuca, Erkan, Akcakanat, Argun, Scott, Stephen M, Arango, Natalia Paez, Zheng, Xiaofeng, Chen, Ken, Tapia, Coya, Tarco, Emily, Eterovic, Agda K, Black, Dalliah M, Litton, Jennifer K, Yap, Timothy A, Tripathy, Debu, Mills, Gordon B, Meric-Bernstam, Funda

“…Breast cancer patients who do not respond to neoadjuvant therapy have a poor prognosis. There is a pressing need for novel targets and models for preclinical…”
Get full text

Efficacy of futibatinib, an irreversible fibroblast growth factor receptor inhibitor, in FGFR-altered breast cancer by Saridogan, Turcin, Akcakanat, Argun, Zhao, Ming, Evans, Kurt W., Yuca, Erkan, Scott, Stephen, Kirby, Bryce P., Zheng, Xiaofeng, Ha, Min Jin, Chen, Huiqin, Ng, Patrick K. S., DiPeri, Timothy P., Mills, Gordon B., Rodon Ahnert, Jordi, Damodaran, Senthil, Meric-Bernstam, Funda

“…Several alterations in fibroblast growth factor receptor (FGFR) genes have been found in breast cancer; however, they have not been well characterized as…”
Get full text

Overexpression of Snail induces epithelial–mesenchymal transition and a cancer stem cell–like phenotype in human colorectal cancer cells by Fan, Fan, Samuel, Shaija, Evans, Kurt W., Lu, Jia, Xia, Ling, Zhou, Yunfei, Sceusi, Eric, Tozzi, Federico, Ye, Xiang‐Cang, Mani, Sendurai A., Ellis, Lee M.

“…Epithelial–mesenchymal transition (EMT) is a critical process providing tumor cells with the ability to migrate and escape from the primary tumor and…”
Get full text

Combined MEK/MDM2 inhibition demonstrates antitumor efficacy in TP53 wild-type thyroid and colorectal cancers with MAPK alterations by Pairawan, Seyed, Akcakanat, Argun, Kopetz, Scott, Tapia, Coya, Zheng, Xiaofeng, Chen, Huiqin, Ha, Min Jin, Rizvi, Yasmeen, Holla, Vijaykumar, Wang, Jing, Evans, Kurt W., Zhao, Ming, Busaidy, Naifa, Fang, Bingliang, Roth, Jack A., Dumbrava, Ecaterina Ileana, Meric-Bernstam, Funda

“…Most tumors with activating MAPK (mitogen-activated protein kinase) pathway alterations respond poorly to MEK inhibitors alone. Here, we evaluated combination…”
Get full text

Ability to Generate Patient-Derived Breast Cancer Xenografts Is Enhanced in Chemoresistant Disease and Predicts Poor Patient Outcomes by McAuliffe, Priscilla F, Evans, Kurt W, Akcakanat, Argun, Chen, Ken, Zheng, Xiaofeng, Zhao, Hao, Eterovic, Agda Karina, Sangai, Takafumi, Holder, Ashley M, Sharma, Chandeshwar, Chen, Huiqin, Do, Kim-Anh, Tarco, Emily, Gagea, Mihai, Naff, Katherine A, Sahin, Aysegul, Multani, Asha S, Black, Dalliah M, Mittendorf, Elizabeth A, Bedrosian, Isabelle, Mills, Gordon B, Gonzalez-Angulo, Ana Maria, Meric-Bernstam, Funda

“…Breast cancer patients who are resistant to neoadjuvant chemotherapy (NeoCT) have a poor prognosis. There is a pressing need to develop in vivo models of chemo…”
Get full text

Epigenetically upregulating TROP2 and SLFN11 enhances therapeutic efficacy of TROP2 antibody drug conjugate sacitizumab govitecan by Zhao, Ming, DiPeri, Timothy P., Raso, Maria Gabriela, Zheng, Xiaofeng, Rizvi, Yasmeen Qamar, Evans, Kurt W., Yang, Fei, Akcakanat, Argun, Roberto Estecio, Marco, Tripathy, Debu, Dumbrava, Ecaterina E., Damodaran, Senthil, Meric-Bernstam, Funda

“…TROP2 antibody drug conjugates (ADCs) are under active development. We seek to determine whether we can enhance activity of TROP2 ADCs by increasing TROP2…”
Get full text

Alternative origins of stroma in normal organs and disease by Kolonin, Mikhail G, Evans, Kurt W, Mani, Sendurai A, Gomer, Richard H

“…Stromal fibroblasts are a new prospective drug target. Mesenchymal stromal cells (MSCs) and monocyte-derived stromal cells, also known as fibrocytes, are…”
Get more information

Oxidative Phosphorylation Is a Metabolic Vulnerability in Chemotherapy-Resistant Triple-Negative Breast Cancer by Evans, Kurt W, Yuca, Erkan, Scott, Stephen S, Zhao, Ming, Paez Arango, Natalia, Cruz Pico, Christian X, Saridogan, Turcin, Shariati, Maryam, Class, Caleb A, Bristow, Christopher A, Vellano, Christopher P, Zheng, Xiaofeng, Gonzalez-Angulo, Ana Maria, Su, Xiaoping, Tapia, Coya, Chen, Ken, Akcakanat, Argun, Lim, Bora, Tripathy, Debu, Yap, Timothy A, Francesco, Maria Emilia Di, Draetta, Giulio F, Jones, Philip, Heffernan, Timothy P, Marszalek, Joseph R, Meric-Bernstam, Funda

“…Oxidative phosphorylation (OXPHOS) is an active metabolic pathway in many cancers. RNA from pretreatment biopsies from patients with triple-negative breast…”
Get full text

Ganglioside GD2 identifies breast cancer stem cells and promotes tumorigenesis by Battula, Venkata Lokesh, Shi, Yuexi, Evans, Kurt W, Wang, Rui-Yu, Spaeth, Erika L, Jacamo, Rodrigo O, Guerra, Rudy, Sahin, Aysegul A, Marini, Frank C, Hortobagyi, Gabriel, Mani, Sendurai A, Andreeff, Michael

“…Cancer stem cells (CSCs) are a small subpopulation of cancer cells that have increased resistance to conventional therapies and are capable of establishing…”
Get full text

Combining Neratinib with CDK4/6, mTOR, and MEK Inhibitors in Models of HER2-positive Cancer by Zhao, Ming, Scott, Stephen, Evans, Kurt W, Yuca, Erkan, Saridogan, Turcin, Zheng, Xiaofeng, Wang, Heping, Korkut, Anil, Cruz Pico, Christian X, Demirhan, Mehmet, Kirby, Bryce, Kopetz, Scott, Diala, Irmina, Lalani, Alshad S, Piha-Paul, Sarina, Meric-Bernstam, Funda

“…Neratinib is an irreversible, pan-HER tyrosine kinase inhibitor that is FDA approved for HER2-overexpressing/amplified (HER2 ) breast cancer. In this…”
Get full text

Adavosertib Enhances Antitumor Activity of Trastuzumab Deruxtecan in HER2-Expressing Cancers by DiPeri, Timothy P, Evans, Kurt W, Raso, Maria Gabriela, Zhao, Ming, Rizvi, Yasmeen Q, Zheng, Xiaofeng, Wang, Bailiang, Kirby, Bryce P, Kong, Kathleen, Kahle, Michael, Yap, Timothy A, Dumbrava, Ecaterina E, Ajani, Jaffer A, Fu, Siqing, Keyomarsi, Khandan, Meric-Bernstam, Funda

“…Cyclin E (CCNE1) has been proposed as a biomarker of sensitivity to adavosertib, a Wee1 kinase inhibitor, and a mechanism of resistance to HER2-targeted…”
Get full text

Utilizing Patient-derived Xenografts to Model Precision Oncology for Biliary Tract Cancer by DiPeri, Timothy P., Evans, Kurt W., Scott, Stephen, Zheng, Xiaofeng, Varadarajan, Kaushik, Kwong, Lawrence N., Kahle, Michael, Tran Cao, Hop S., Tzeng, Ching-Wei, Vu, Thuy, Kim, Sunhee, Su, Fei, Raso, Maria Gabriela, Rizvi, Yasmeen, Zhao, Ming, Wang, Huamin, Lee, Sunyoung S., Yap, Timothy A., Rodon, Jordi, Javle, Milind, Meric-Bernstam, Funda

“…Abstract Purpose: Biliary tract cancers (BTCs), which are rare and aggressive malignancies, are rich in clinically actionable molecular alterations. A major…”
Get full text

Convergent MAPK pathway alterations mediate acquired resistance to FGFR inhibitors in FGFR2 fusion-positive cholangiocarcinoma by DiPeri, Timothy P., Zhao, Ming, Evans, Kurt W., Varadarajan, Kaushik, Moss, Tyler, Scott, Stephen, Kahle, Michael P., Byrnes, Charnel C., Chen, Huiqin, Lee, Sunyoung S., Halim, Abdel-Baset, Hirai, Hiroshi, Wacheck, Volker, Kwong, Lawrence N., Rodon, Jordi, Javle, Milind, Meric-Bernstam, Funda

“…There is a knowledge gap in understanding mechanisms of resistance to fibroblast growth factor receptor (FGFR) inhibitors (FGFRi) and a need for novel…”
Get full text

Targeting PI3Kβ alone and in combination with chemotherapy or immunotherapy in tumors with PTEN loss by Owusu-Brackett, Nicci, Zhao, Ming, Akcakanat, Argun, Evans, Kurt W, Yuca, Erkan, Dumbrava, Ecaterina Ileana, Janku, Filip, Meric-Bernstam, Funda

“…PTEN-deficient tumors are dependent on PI3Kβ activity, making PI3Kβ a compelling target. We evaluated the efficacy of PI3Kβ inhibitor AZD8186 on tumors with…”
Get full text

Expression of epithelial-mesenchymal transition-inducing transcription factors in primary breast cancer: The effect of neoadjuvant therapy by Mego, Michal, Mani, Sendurai A., Lee, Bang-Ning, Li, Changping, Evans, Kurt W., Cohen, Evan N., Gao, Hui, Jackson, Summer A., Giordano, Antonio, Hortobagyi, Gabriel N., Cristofanilli, Massimo, Lucci, Anthony, Reuben, James M.

“…Epithelial cancer cells are likely to undergo epithelial–mesenchymal transition (EMT) prior to entering the peripheral circulation. By undergoing EMT,…”
Get full text